Subsection 3a: Mutual recognition procedure and decentralised procedure

At the end of the Community arbitration procedure implemented in accordance with the provisions of Articles R. 5121-51-8 and R. 5121-51-9, the Director General of the Agence nationale de sécurité du médicament et des produits de santé shall grant, vary, suspend or revoke the marketing authorisation within a period of thirty days, in accordance with the decision taken by the European Commission at the end of this procedure.